nQ is committed to brave research

Our focus is the discovery, development, and commercialization of computationally-derived digital biomarkers for people living with neurodegenerative diseases.

nQ Medical, Inc. is pioneering digital biomarker development to accelerate research, advance disease detection, and improve care.  nQ’s Digital Neurology is powered by AI analysis of passive personal device interactions.  Based on research begun at MIT, our first computationally derived digital biomarker for Parkinson's disease has received FDA Breakthrough Designation and our de novo application will be submitted at the end of March 2022.  FDA clearance is expected within six months; the Software As a Medical Device (SaMD) was submitted in the market March 2022.

nQ's goal is to bring accurate, affordable, and accessible digital tools to people everywhere.  This supports a broad range of neurodegenerative diseases (as well as other disorders involving motor function and cognition) in early detection, remote patient monitoring, and improved treatment pathways.  Our NeuroCare product helps health systems deliver digital neurology outside the four walls of the hospital.

We have assembled an exceptional team of data scientists, engineers, neurologists, and company builders who are committed to conquering one of the greatest medical challenges of our generation.

We believe in...

Improving livesCollaborationIntegrityTrustBrave ResearchAccountabilityInclusiveness

Our Vision

nQ Medical is pioneering digital biomarker development to accelerate research, enhance disease detection, and improve care.

Our Mission

To improve lives, by enabling the discovery and development of digital biomarkers.

The nQ Medical Journey



NeuroQwerty Project Launched @ MIT with Support of MJFF



nQ Medical, Inc

nQ Medical, Inc. founded in Kendall Square, Cambridge, MA


Research Initiative Expanded

Parkinson’s Disease (PD) Research Initiative Expanded



US Patent Issued

US Patent 9,867,573 Issued


Alzheimer’s Disease

Alzheimer’s Disease (AD) Research Initiative @ Cleveland Clinic with Support of Biogen



Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) Research Initiative @ MGH with Support of MT Pharma


A Breakthrough

FDA Breakthrough Designation Awarded



Another Patent

US Patent 10,506,979 Issued



Partnership with Davis-Phinney Foundation



New patent Issued

US Patent 10,959,676 Issued



Expansion to Japan


nQ Medical Biomaker platform developer

Our Mission is to improve lives by enabling the discovery and development of digital biomarkers.

Technology Links

Company Links

Contact Info

nQ Medical’s software has been granted breakthrough device designation but is not yet cleared by the FDA. Any depictions of the technology are intended to be conceptual and illustrative and are not intended to convey exact representations of anatomy, physiology, structure, positioning, or performance of the technology.